|
Genzyme Corp
1 Kendall Square
Cambridge
MA 02139-1562
| Telephone |
(617) 252-7500
|
| Fax |
(617) 252-7600
|
| URL |
http://www.genzyme.com |
Genzyme Corp, a biotechnology and healthcare products
company, focuses on developing products and services for
major unmet medical needs. Genzyme Corp has three divisions.
Genzyme General develops and markets healthcare products
and services, including therapies for rare genetic diseases and
other specialised therapeutics, genetic diagnostic services, and
diagnostic products. Genzyme Biosurgery develops and
markets a range of medical devices, biomaterials and
biotherapeutics for the cardiothoracic, orthopaedic and general
surgery markets. Genzyme Molecular Oncology develops
molecular cancer therapies in the areas of cancer vaccines and
antiangiogenesis through genomics, gene therapy, genetic
diagnostics, and a small molecule combinatorial chemistry drug
discovery programme. Genzyme Corp employs more than
4,000 staff worldwide.
Additional notes
In December 2000, two Genzyme divisions, Genzyme Surgical
Products and Genzyme Tissue Repair, were merged with
Biomatrix Inc to form Genyme Biosurgery.
Year founded 1981
Total staff at main site More than 1000
Financial data for year ending 31/12/2000
Revenues: $903.320M
Net profit (after tax): $62.940M
Research expenditure: $169.478M
Stock exchanges [ticker symbols, if any]
NASDAQ [GENZ]
Products and Services
Diagnostic tests; Drug delivery systems; Enzymes (research); Immunoassays; Laboratory chemicals; Medical devices; Peptide synthesis; Therapeutic biologicals; Therapeutic drugs; Vaccines
Interest Areas
Bioethics; Bioinformatics; Biomaterials; Cardiology; Cell biology; Cell/tissue culture; Clinical diagnostics; Combinatorial chemistry; Diabetes; Drug design/development; Enzymology; Gene therapy; Genetic diseases; Genetic engineering; Genetics; Genomics; Human
healthcare; Immunology; Infectious diseases; Neurodegenerative diseases; Oncology/cancer; Pharmaceuticals; Protein engineering; Surgery
|
Key executives
Mr Earl M Collier, Jr
Executive Vice President and President, Biosurgery
Mr Thomas J DesRosier
Senior Vice President, General Counsel, and Chief Patent Counsel
Mr Richard H Douglas
Senior Vice President, Corporate Development
Mr David D Fleming
Group Senior Vice President
Mr Elliot D Hillback, Jr
Senior Vice President, Corporate Affairs
Mr Evan M Lebson
Vice President and Tresurer
Dr John M McPhearson
Senior Vice President, Protein Development
Dr Richard A Moscicki
Senior VP, Clinical, Medical, Clinical and Regulatory Affairs and Chief Medical Officer
Dr Frank Ollington
Senior Vice President, Operations
Ms Lisa J Raines
Senior Vice President, Government Relations
Dr Alan E Smith
Senior Vice President, Research, and Chief Scientific Officer (CSO)
Mr Henri A Termeer
Chairman, President and Chief Executive Officer (CEO)
Mr Michael S Wyzga
SVP Finance, Corporate Controller, CFO and Chief Accounting Officer
Mr G Jan van Heek
Executive Vice President, Therapeutics and Genetics
|